CMEducation Resources, LLC

CMEducation Resources, LLC - publications, events, lectures

Street address
United States
Founded at
2013-02-21
Website
Views
1250
Description
CMEducation Resources, LLC is a full-service provider of innovative, integrated, multi-platform CME programs that, every month, engage more than 160,000 unique physicians and allied healthcare professionals across multiple primary care and specialty-focused disease states. As one of the most creative, technologically-advanced medical education companies in the world, we offer a unique combination of scientifically rigorous, dynamic, and innovative CME programs that have garnered 34 eHealthcare Leadership Awards over the past three years.

Melding ultra-rigorous scientific content with meticulous compliance-adherence processes and quality reviews, CMEducation programs have an established track record producing attendance record-breaking symposia and summits, the impact of which is substantiated by measurable outcomes in the domains of performance improvement, guideline adherence, and knowledge acquisition.

For the past 10 years, CMEducation's activities have galvanized motivated learners—primary care physicians, clinical specialists, investigators and leading global authorities—around educational activities that optimize the quality and effectiveness of patient care at the front lines of clinical practice.

Shared content

  • Videos 0
  • Images 0
  • Events 17
  • Publications 0
  • eBooks 0
  • eLearning 0
  • Playlists 0

No materials in this category / section. Be first and


upload your material

No materials in this category / section. Be first and


upload your material

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 1953

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2047

  Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2128

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2301

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2253

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2476

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2355

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2215

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2202

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 1962

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2061

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 1949

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2012

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2142

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 1962

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Minimizing Risks and Maximizing Efficacy for Management...

Past events Fee: Not specified Views: 2012

 Multiple sclerosis (MS) affects nearly 400,000 people in the United States and over 2.5 million people worldwide. Diagnostic methods and treatment plans developed...

Optimizing the Risk-Benefit Therapeutic Equation for...

Past events Fee: Not specified Views: 2334

 Neurologic specialists and their patients understand that multiple sclerosis (MS) is a lifelong, immune-mediated progressive disorder. The early age of onset...

No materials in this category / section. Be first and


upload your material

Nothing was found.



Add eBook

Nothing was found.



Add new course

Nothing was found.